| Q73342793 | Acute thrombosis of a separate major coronary artery during initially successful thrombolytic therapy |
| Q73364963 | Adjunctive Therapy with an Antithrombotic Drug Can Prevent Reocclusion and Induce Residual Thrombus Reduction After Percutaneous Transcatheter Angioplasty of the Thrombotic Lesions |
| Q35359038 | Advances in thrombolytic therapy |
| Q35956473 | Amino-Terminal Fusion of Epidermal Growth Factor 4,5,6 Domains of Human Thrombomodulin on Streptokinase Confers Anti-Reocclusion Characteristics along with Plasmin-Mediated Clot Specificity |
| Q90030308 | An ATF6-tPA pathway in hepatocytes contributes to systemic fibrinolysis and is repressed by DACH1 |
| Q41046059 | Antiplatelet and anticoagulant use after myocardial infarction |
| Q54035550 | Combination of a direct thrombin inhibitor and a platelet glycoprotein IIb/IIIa blocking peptide facilitates and maintains reperfusion of platelet-rich thrombus with alteplase. |
| Q42700964 | Comparative effects of anti-platelet agents as adjuncts to tissue plasminogen activator in a dog model of occlusive coronary thrombosis |
| Q73635471 | Comparison of Argatroban and Hirudin for the Reperfusion of Thrombotic Arterial Occlusion by Tissue Plasminogen Activator |
| Q72592884 | Correlation between clinical course and quantitative analysis of the ischemia related artery in patients with unstable angina pectoris, refractory to medical treatment. Results of two randomized trials. The European Cooperative Study Group |
| Q77535794 | Current issues in reperfusion therapy |
| Q33610416 | Enhanced thrombolytic efficacy and reduction of infarct size by simultaneous infusion of streptokinase and heparin |
| Q33613657 | Enzymatic evidence of impaired reperfusion in diabetic patients after thrombolytic therapy for acute myocardial infarction: a role for plasminogen activator inhibitor? |
| Q74098998 | Fibrin specificity and procoagulant effect related to the kallikrein-contact phase system and to plasmin generation with double-bolus reteplase and front-loaded alteplase thrombolysis in acute myocardial infarction |
| Q71551077 | Frequency of "optimal anticoagulation" for acute myocardial infarction after thrombolysis with front-loaded recombinant tissue-type plasminogen activator and conjunctive therapy with recombinant hirudin (HBW 023). ALKK Study Group |
| Q40433419 | From the experimental myocardial infarction to the clinical acute myocardial infarction: limitations of thrombolytic therapy |
| Q73295945 | Guidelines for the Management of Patients with Acute Myocardial Infarction |
| Q40433776 | Heparin as adjunctive therapy to coronary thrombolysis in acute myocardial infarction |
| Q74267651 | Human platelet activation by thrombolytic agents: effects of tissue-type plasminogen activator and urokinase on platelet surface P-selectin expression |
| Q54084235 | Increased thrombin activity correlates with increased ischemic event rate after percutaneous transluminal coronary angioplasty: lack of efficacy of locally delivered urokinase. |
| Q43942828 | Influence on coagulation activity by subcutaneous LMW heparin as an adjuvant treatment to fibrinolysis in acute myocardial infarction |
| Q37932377 | Intravenous streptokinase. A reappraisal of its therapeutic use in acute myocardial infarction |
| Q40485987 | Is thrombolysis alone the best therapy for acute myocardial infarction? Current status and emerging strategies |
| Q73364768 | Issues Regarding the Use of Heparin Following Streptokinase Therapy |
| Q47339841 | Local treatment with an antithrombotic drug reduces thrombus size in coronary and peripheral thrombosed arteries |
| Q71827329 | Local treatment with antithrombotic drugs can prevent thrombus formation: An angioscopic and angiographic study |
| Q73295821 | Novel Antithrombotic Strategies for the Treatment of Coronary Artery Thrombosis: A Critical Appraisal |
| Q33699902 | Optimal management of acute myocardial infarction at the dawn of the next millennium |
| Q71129084 | Pathophysiology of coronary artery disease |
| Q73365821 | Physicians' Use of Heparin Following Thrombolytic Therapy: An International Perspective |
| Q61669298 | Plasma level changes of fibrinopeptide a after uncomplicated coronary angioplasty |
| Q73295940 | Platelet Activity in the Early Stage of Acute Myocardial Infarction: Relation to Time of Presentation, Treatment with Either Tissue Plasminogen Activator or Streptokinase and Cyclooxygenase Inhibition |
| Q67883906 | Possible role of vascular intima for generation of coagulant activity in patients undergoing coronary thrombolysis with recombinant tissue-type plasminogen activator. A randomized, placebo-controlled study |
| Q35224546 | Principles Underlying the Use of Conjunctive Agents with Plasminogen Activators |
| Q67924061 | Principles and practice of coronary thrombolysis and conjunctive treatment |
| Q67485368 | Prolonged Coagulation Instability is Associated with a Higher‐dose Regimen of Tissue‐type Plasminogen Activator in Patients with Acute Myocardial Infraction |
| Q68769297 | Reperfusion in acute myocardial infarction |
| Q71974513 | Role of Thrombin Compared With Factor Xa in the Procoagulant Activity of Whole Blood Clots |
| Q34308795 | Role of thrombin and thromboxane A2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator |
| Q79366424 | Specific types of activated Factor XII increase following thrombolytic therapy with tenecteplase |
| Q40726003 | Streptokinase. A review of its pharmacology and therapeutic efficacy in acute myocardial infarction in older patients |
| Q41871561 | Sustained reflow in dogs with coronary thrombosis with K2P, a novel mutant of tissue-plasminogen activator |
| Q73132674 | TIMI grade 3 flow and reocclusion after intravenous thrombolytic therapy: a pooled analysis |
| Q34376928 | The thrombolytic paradox |
| Q73681259 | Thrombin Generation in Patients with Acute Myocardial Infarction Treated with Front-Loaded rt-PA and Recombinant Hirudin (HBW 023) |
| Q56945190 | Thrombin Generation, Inhibition and Clinical Outcomes in Patients With Acute Myocardial Infarction Treated With Thrombolytic Therapy and Heparin: Results From the GUSTO-I Trial fn1fn1This study was supported by Genentech, Inc., South San Francisco, C |
| Q77931289 | Thrombin generation and fibrinolytic activities among patients receiving reduced-dose alteplase plus abciximab or undergoing direct angioplasty plus abciximab for acute myocardial infarction |
| Q53015487 | Thrombolysis in thromboembolic diseases. |
| Q40433424 | Thrombolytic and antithrombotic treatment in myocardial infarction: main achievements and future perspectives |
| Q40735993 | Thrombolytic retreatment with tissue plasminogen activator for threatened reinfarction and thrombotic coronary reocclusion |
| Q33663297 | Use of glycoprotein IIb/IIIa inhibition plus fibrinolysis in acute myocardial infarction |
| Q57798992 | Usefulness of fibrinogenolytic and procoagulant markers during thrombolytic therapy in predicting clinical outcomes in acute myocardial infarction |